CLAIMS

WHAT IS CLAIMED IS:

1. ~~A method of~~ Use of a therapeutically effective amount of an agent that disrupts TBL1 interaction with a coactivator molecule in the manufacture of a medicament for treating and/or preventing a disorder selected from the group consisting of a myeloproliferative neoplasia, chronic myeloid leukemia and acute myeloid leukemia~~comprising administering to a patient in need thereof a therapeutically effective amount of an agent that disrupts TBL1 interaction with a coactivator molecule~~.

~~2. The method use of claim 1, wherein said disorder is cancer.~~

~~3~~2. The ~~method~~ use of claim ~~2~~1, wherein said ~~cancer comprises~~disorder is myeloproliferative neoplasia.

~~4~~3. The use ~~method~~ of claim ~~2~~1, wherein said disorder is~~cancer comprises~~ chronic myeloid leukemia.

~~5~~4. The use ~~method~~ of claim ~~2~~1, wherein said ~~cancer comprises~~disorder is acute myeloid leukemia.

~~6~~5. The use ~~method~~ of claim 1, wherein said coactivator molecule is beta-catenin.

~~7~~6. The use ~~method~~ of claim 1, wherein said agent has the following structure:



or a pharmaceutically acceptable salt thereof.

~~8~~7. ~~A method of treating and/or preventing a disorder comprising administering to a patient in need thereof a therapeutically effective amount of an agent that disrupts TBL1 interaction with a coactivator molecule~~The use of claim 1, wherein said agent is provided further in combination with an agent that inhibits JAK2 kinase, BCR-ABL kinase, or histone deacetylase.

~~98~~. The ~~method~~ use of claim ~~87~~, wherein said agent has the following structure:



or a pharmaceutically acceptable salt thereof.

~~109~~. The ~~method~~ use of claim ~~98~~, wherein said TBL1 is selected from the group consisting of Transducin (beta)-like 1X-linked (TBL1X), Transducin (beta)-like 1Y-linked (TBL1Y) and Transducin (beta)-like R1-linked TBLR1 proteins.